A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma

Summary

This is a study to determine the safety of CDX-014 and effectiveness (how well the drug works).

Timeline

Start

2016-06

Primary completion

2018-11-16

Completion

2018-11-16

Outcome

Outcome not reported

Stopped: “Development of CDX-014 discontinued”

Publications

• Results McGregor BA, Gordon M, Flippot R, Agarwal N, George S, Quinn DI, Rogalski M, Hawthorne T, Keler T, Choueiri TK. Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma. Invest New Drugs. 2020 Dec;38(6):1807-1814. doi: 10.1007/s10637-020-00945-y. Epub 2020 May 29.

Drugs

Indications